Cherry (C3RY) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
1 Sep, 2026Executive summary
Strategic transformation focused on stabilizing, simplifying, and prioritizing core business segments, with Project Blossom driving operational improvements and growth initiatives.
Leadership continuity established with CEO appointment and management demonstrating commitment by oversubscribing in the rights issue.
Rights issue completed, raising €10.1 million to strengthen the balance sheet and support ongoing transformation.
Financial highlights
H1 2026 Group revenue reached €40.0 million, up 3% year-over-year on a comparable basis, despite challenging market conditions.
Adjusted EBITDA improved to €-4.0 million from €-10.2 million year-over-year, driven by cost reductions and margin improvements.
Gross margin increased by 12 percentage points year-over-year, with group gross margin rising from 36.8% to 43.4% and peripherals margin from 41.7% to 45.1%.
Working capital reduced from €45.1 million to €25.3 million, highlighting focus on cash generation and operational efficiency.
Cash balance at end of June was €4.3 million, further strengthened by a €10.1 million capital increase.
Outlook and guidance
Targeting breakeven at €85 million revenue and 44% gross margin for Peripherals by 2027.
H2 growth in peripherals is uncertain due to ongoing inventory normalization, but focus remains on preparing for 2027 targets.
Project Blossom expected to drive top-line growth and further cost reductions, with a clear path to sustainable profitability.
Key priorities include completing the sale of DH&S, repaying debt, and executing Project Blossom to reduce costs and return to growth.
Clear strategy to stabilize, simplify, and focus, with disciplined execution and strong focus on cash and working capital.
Latest events from Cherry
- Revenue fell 17.8% but margin gains and cost controls improved results amid transformation.C3RY
Q1 2026 - 2025 revenue fell 15% to €94.3m, with restructuring, cost cuts, and segment review ongoing.C3RY
Q4 2025 - 2024 guidance targets €140m–€150m revenue and a 7–8% EBITDA margin, signaling a strong turnaround.C3RY
Investor presentation - Revenue and EBITDA fell short, triggering cost cuts and a revised €120m 2024 outlook.C3RY
Investor presentation - Streamlined for margin-driven growth, with €120M 2024 revenue forecast and €3.5M cost savings.C3RY
Investor presentation - Restructuring, M&A, and operational streamlining target a return to growth and financial stability.C3RY
Investor presentation - Revenue dropped 25% in H1 2025, with negative EBITDA and liquidity boosted by asset sales.C3RY
Q2 2025 - Q3 2024 results missed expectations, triggering restructuring and a cut in full-year guidance.C3RY
Q3 2024 TU - Digital Health & Solutions drove revenue growth, but margin pressure and restructuring widened net loss.C3RY
Q2 2024